Withings' ScanWatch has received FDA clearance, paving the way for the watches to be sold in the US starting in November, the company announced. The watches have simultaneously been cleared to take electrocardiogram (ECG) and SpO2 (oxygen saturation) readings, in health and medical settings.
The original ScanWatch has been available in Europe since it came out a year ago, but FDA clearance has taken much longer. Both models use ECG readings to check for atrial fibrillation (heartbeat irregularities), and you can even download the results and mail them to your doctor as a PDF. If it notices any irregular heartbeats, it will advise you to take an ECG test.
We found the ScanWatch to be the best hybrid smartwatch out there, offering good looks analog dials and a small PMOLED display to display activities, heartrate, ECG, SpO2 and more. As with Withings' scales and other health devices, it works with the company's Health Mate app.
Sales will start in early November 2021, starting at $279 for the original ScanWatch 38mm model. The Rose Gold and Horizon versions will will be available in early 2022 with prices starting at $299 and $499 respectively.